De­ci­pher­a's TKI drug flops key test in ear­li­er-line GI tu­mors, send­ing stock in­to a tail­spin

De­spite a very late line ap­proval for its TKI drug last year, De­ci­phera has had its eyes set on crack­ing in­to ear­li­er pa­tients with GI tu­mors — a pos­si­bil­i­ty in­vestors cheered. But that door has now been slammed shut, and De­ci­phera’s cheer­lead­ers are flee­ing in droves.

De­ci­phera’s Qin­lock (ripretinib) failed a head-to-head matchup against stan­dard-of-care suni­tinib in sec­ond-line pa­tients with gas­troin­testi­nal stro­mal tu­mors (GIST) who had pre­vi­ous­ly been treat­ed with TKI in­hibitor ima­tinib, the biotech ad­mit­ted Fri­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA